On August 1, 2018, Angiochem Inc. announced that it had completed its Series C financing round of $7.5 million.
Angiochem Inc. plans to use the financing to support the development of ANG1005, its treatment for leptomeningeal carcinomatosis caused by breast cancer. There are currently no approved therapeutic treatment options for this disease.
Angiochem Inc. is a Montréal-based clinical-stage biotechnology company discovering and developing new breakthrough drugs to treat a wide range of neurological diseases.
Osler, Hoskin & Harcourt LLP represented Angiochem Inc. with a team consisting of Nathalie Beauregard, Calvin Leung and Jean-Philippe Bertrand (Corporate).